Skip to content

Study · Randomized controlled trial · n = 18 · 2005

4 results

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes.

Ceriello A, Piconi L, Quagliaro L, Wang Y, Schnabel CA, Ruggles JA, Gloster MA, Maggs DG, Weyer C

Diabetes care1 Mar 2005Cited by 46 (Europe PMC)

PMID15735200 (opens in a new tab)DOI10.2337/diacare.28.3.632 (opens in a new tab)PepBankPUB-15735200
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In type 1 diabetes, pramlintide reduced postprandial glucose excursions compared with placebo.

    In plain wordsIn type 1 diabetes, pramlintide reduced glucose rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial glucose excursions
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, pramlintide treatment significantly reduced postprandial excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP (P < 0.03 for all comparisons).
    2 context sentences
    Summary · context
    In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin.
    Summary · context
    The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.
  2. 02HumanRandomized controlled trialMechanism

    In type 1 diabetes, pramlintide reduced postprandial nitrotyrosine excursions compared with placebo.

    In plain wordsIn type 1 diabetes, pramlintide reduced nitrotyrosine rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial nitrotyrosine excursions
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Oxidative stress · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, pramlintide treatment significantly reduced postprandial excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP (P < 0.03 for all comparisons).
    2 context sentences
    Summary · context
    In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin.
    Summary · context
    The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.
  3. 03HumanRandomized controlled trialMechanism

    In type 1 diabetes, pramlintide reduced postprandial oxidized LDL excursions compared with placebo.

    In plain wordsIn type 1 diabetes, pramlintide reduced oxidized LDL rises after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreasePostprandial oxidized LDL excursions
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Oxidative stress · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, pramlintide treatment significantly reduced postprandial excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP (P < 0.03 for all comparisons).
    2 context sentences
    Summary · context
    In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin.
    Summary · context
    The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.
  4. 04HumanRandomized controlled trialMechanism

    In type 1 diabetes, pramlintide prevented a postprandial decline in TRAP compared with placebo.

    In plain wordsIn type 1 diabetes, pramlintide prevented a decline in antioxidant capacity after meals compared with placebo.

    Peptide
    Pramlintide (Symlin)
    Outcome
    IncreaseTotal radical-trapping antioxidant parameter
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Oxidative stress · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Compared with placebo, pramlintide treatment significantly reduced postprandial excursions of glucose, nitrotyrosine, and ox-LDL and prevented a decline in TRAP (P < 0.03 for all comparisons).
    2 context sentences
    Summary · context
    In a randomized, single-blind, placebo-controlled, crossover study, 18 evaluable subjects with type 1 diabetes underwent two standardized breakfast meal tests and received pramlintide or placebo in addition to their preprandial insulin.
    Summary · context
    The plasma concentrations of glucose and markers of oxidative stress (nitrotyrosine, oxidized LDL [ox-LDL], and total radical-trapping antioxidant parameter [TRAP]) were measured at baseline and during the 4-h postprandial period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.